Sucraid® (sacrosidase) Oral Solution is an enzyme replacement that facilitates breakdown of sucrose (sugar) into simpler forms for absorption from the intestine into the blood. It can help relieve the gastrointestinal symptoms associated with Genetic Sucrase-Isomaltase Deficiency/Congenital Sucrase-Isomaltase Deficiency, and as a result, patients can maintain a more normal diet with respect to sucrose-containing foods.
In 1960, Weijers and colleagues discovered Congenital Sucrase-Isomaltase Deficiency, an autosomal recessive disease of the small intestine that is also known as Genetic Sucrase-Isomaltase Deficiency. The disease was originally characterized by undetectable sucrase activity, a decrease of maltase activity to nearly one third of the normal level and a varying degree of isomaltase activity.
Sucraid® does not break down starch (e.g., potato, bread, pasta) and some Genetic Sucrase-Isomaltase Deficiency patients also have an inability to absorb starch from their diet. It is advisable for patients to restrict the amount of dietary starch for two weeks when starting Sucraid® and gradually reintroduce starch. Keeping a dietary diary for the first few weeks of therapy is also recommended.
Sucraid® is a sucrase enzyme replacement therapy that catalyzes the hydrolysis of sucrose into glucose and fructose, thereby facilitating absorption from the small intestine into the bloodstream. Sucraid® has been shown to be an effective treatment for patients with Genetic Sucrase-Isomaltase Deficiency. The sacrosidase in Sucraid® is potent and robust; on a per milliliter basis, Sucraid® is approximately 100-fold more potent than endogenous sucrase.1 It has been shown to be stable when stored at 4°C.2
Although Sucraid® provides replacement therapy for deficient sucrase, it does not provide specific replacement therapy for deficient isomaltase.3 Therefore, restricting starch in the diet may still be necessary to reduce symptoms as much as possible. The need for dietary starch restriction for patients using Sucraid® should be evaluated in each patient.